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Abstract
Insulin-like growth factor I (IGF-I) potently stimulates intestinal growth. Insulinreceptorsubstrate-1
(IRS-1)mediates proliferative and antiapoptotic actions of IGF-I in cell lines, but its in vivo relevance
in intestine is not defined. This study tested the hypothesis that there is cell type-specific dependence
on IRS-1 as a mediator of IGF-I action. Length, mass, crypt cell proliferation, and apoptosis were
measured in small intestine and colon of IRS-1-null mice and wild-type (WT) littermates and in colon
of IRS-1-null or WT mice expressing IGF-I transgenes. Expression of IGF-I receptor and signaling
intermediates was examined in intestine of WT and IRS-1-null mice, cultured intestinal epithelial
cells, and myofibroblasts. Absolute IRS-1 deficiency reduced mucosal mass in jejunum and colon,
but effects were more pronounced in colon. Muscularis mass was decreased in both segments. In
IGF-I transgenics, IRS-1 deficiency significantly attenuated IGF-I-stimulated growth of colonic
mucosa and abolished antiapoptotic but not mitogenic effects of IGF-I transgene on crypt cells. IGF-
I-induced muscularis growth was unaffected by IRS-1 deficiency. In intestinal epithelial cells, IRS-1
was expressed at higher levels than IRS-2 and was preferentially activated by IGF-I. In contrast, IGF-
I activated both IRS-1 and IRS-2 in intestinal myofibroblasts and IRS-2 activation was upregulated
in IRS-1-null myofibroblasts. We conclude that the intestinal epithelium but not the muscularis
requires IRS-1 for normal trophic actions of IGF-I and that IRS-1 is required for antiapoptotic but
not mitogenic effects of IGF-I in the intestinal crypts in vivo.
Systemic insulin-like growth factor (IGF-I) potently increases growth of the small intestine
and colon, and elevated circulating IGF-I increases the risk of intestinal cancer (7). Studies in
transgenic mice that overexpress IGF-I demonstrate both endocrine and local autocrine or
paracrine actions of IGF-I on bowel growth in vivo (15,16,25,28). Mice that overexpress a
human IGF-I transgene driven by a mouse metallothionein-1 promoter (MT-hIGF-I
transgenics) exhibit significant increases in small bowel length, mass of small bowel mucosa,
and crypt cell proliferation (15). These effects may derive from endocrine effects of the elevated
circulating IGF-I that occur in this model or from autocrine or paracrine actions of transgene-
derived IGF-I, which is locally overexpressed in intestine of these mice (15). SMP8-IGF-I
transgenic mice have a rat IGF-I transgene driven by the smooth muscle α-actin SMP8
promoter. These mice have normal plasma levels of IGF-I but show high-level expression of
the IGF-I transgene specifically in enteric smooth muscle layers, leading to overgrowth of
muscularis layers (25,28).
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The type 1 IGF receptor (IGF-IR) is the primary mediator of the growth-promoting effects of
IGF-I in vitro and in vivo (3). The IGF-IR is a receptor tyrosine kinase and is expressed
throughout the intestine (11,21). IGF-I induces autophosphorylation of the IGF-IR and
subsequent, rapid tyrosine phosphorylation of several early intracellular signaling proteins,
including insulin receptor substrates (IRS-1 and IRS-2) and Src homology 2 domain and
collagen protein (Shc) (3,13). Considerable in vitro evidence, derived largely from embryonic
or cancer cell lines, indicates that IRS-1 is a major intracellular mediator of the proliferative
and antiapoptotic actions of IGF-I (2,3). Mice that are homozygous for IRS-1 gene deletion
(IRS-1−/−) exhibit reduced body weight and reduced weight of a number of organs, but the
magnitude of growth impairment differs among organs (16). In IRS-1-null mice, the weight of
the small intestine is preserved more than body weight or the weight of the gastrocnemius
muscle but is impaired more than brain weight (16). The intermediate growth dependence of
the small intestine on IRS-1 prompted us to analyze intestinal growth in IRS-1-null mice in
more detail to test the hypothesis that there are cell type-specific differences in the requirement
for IRS-1 as an in vivo mediator of intestinal growth. We therefore examined growth of the
mucosa and muscularis in the small intestine and colon of IRS-1-null mice and wild-type (WT)
littermates.
Intestinal growth deficits in IRS-1-null mice may reflect impaired actions of IGF-I but could
reflect impaired actions of other hormones that utilize IRS-1 as a signaling intermediate,
including insulin or growth hormone (3,16). IGF-I transgenic mice cross-bred with IRS-1-null
mice provide a useful model to directly assess whether the growth-promoting effects of IGF-
I on the intestinal mucosa or muscularis layers in vivo require IRS-1. We therefore examined
growth of colonic mucosa and muscularis layers in MT-hIGF-I transgenic or SMP8-IGF-I
transgenic mice that have two functional IRS-1 alleles (IRS-1+/+) or are homozygous for IRS-1
gene disruption (IRS-1−/−). We focused our analyses on colon because initial studies in IRS-1-
null mice revealed major growth deficits in both mucosa and muscularis layers of the colon.
In addition, despite considerable evidence for a role of IGF-I in colorectal cancer (5),
surprisingly little is known about the in vivo actions of IGF-I in normal colon or its mechanisms
of action. Our findings provide novel evidence that IRS-1 deficiency impairs IGF-I action on
the intestinal mucosa but not the muscularis. Moreover, we show that in vivo antiapoptotic but
not proliferative actions of IGF-I on the crypt epithelium require IRS-1.
EXPERIMENTAL PROCEDURES
IRS-1−/−, IRS-1+/−, and IRS-1+/+ mice
Founder mice heterozygous for targeted disruption of the IRS-1 gene (1) were provided by C.
Ronald Kahn (Joslin Diabetes Center, Boston, MA). IRS-1+/− males and females were bred to
generate mice with zero copies (IRS-1−/−), one copy (IRS-1+/−), or two copies (IRS-1+/+) of
the IRS-1 gene. Genotypes were identified by PCR on tail DNA as previously described (1,
16). Analyses focused on mice with zero or two copies of the IRS-1 gene, because previous
studies indicate only very small intestinal growth deficits in IRS-1+/− mice (16). IRS-1−/− mice
were compared directly with IRS-1+/+ littermates to eliminate interlitter variation.
WT and IGF-I transgenic mice with zero or two copies of the IRS-1 gene
Transgenic mice with germline integration of a human IGF-I transgene driven by the mouse
metallothionein-1 promoter (MT-hIGF-I) were generated in our laboratories (15). Cross-
breeding of IGF-I transgenics and mice with IRS-1 deficiency has been described in detail
previously (16). MT-hIGF-I and WT mice with zero or two functional IRS-1 alleles were
analyzed. All mice were given 25 mM zinc sulfate in drinking water to ensure maximal
expression of the metallothionein promoter-driven IGF-I transgene in MT-hIGF-I transgenics.
Genotype of cross-bred animals was established by PCR on tail DNA (1,16). SMP8-IGF-I
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transgenic hemizygous males (25) were bred with IRS-1+/−/WT females to generate mice that
were IRS-1+/− and hemizygous for the SMP8-IGF-I transgene (IRS-1+/−/SMP8-IGF-I). These
mice were then bred with IRS-1+/−/WT mice to yield WT or SMP8-IGF-I mice with zero, one,
or two functional IRS-1 alleles. IRS-1 genotype was identified by PCR on tail DNA. SMP8-
IGF-I transgenic mice and WT mice were identified by Southern blotting on tail DNA as
described previously (25). All studies were performed in adult 50- to 60-day-old mice.
Assays of bowel growth mass, histology, and crypt cell proliferation
Animals were anesthetized with pentobarbital (100 μg/g body wt). Small intestine was
dissected from the ligament of Treitz to the ileocecal valve, the entire colon excluding the
cecum was dissected, and the length and weight were recorded. Corresponding segments of
jejunum and colon were collected for more-detailed analyses.
Protein, DNA content, and sucrase activities were assayed as previously described (15,22).
Hematoxylin and eosin-stained sections of jejunum and colon were examined qualitatively to
complement the biochemical assays. Crypt cell mitoses were measured directly in
microdissected whole crypts prepared from jejunum and colon by established methods (15,
22). The numbers of mitotic cells per crypt were assayed on 20 well-oriented crypts for each
specimen by a single investigator who was unaware of the animal groupings. Apoptosis was
assessed by morphological assays that have been verified to yield data equivalent to other
methods such as terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling
(27). Myocyte density in muscularis layers was assayed by counting nuclei per unit area (1,000
μm2) on hematoxylin and eosin-stained sections.
Expression of IGF-I signaling molecules in the intestine
Mucosal scrapings and muscularis layers from jejunum and colon were homogenized in
extraction buffer (50 mM HEPES, pH = 7.5, 150 mM NaCl, 20 mM sodium pyrophosphate,
100 mM NaF, 1.5% Triton X-100, 10 mM EDTA) plus protease inhibitors (2 mM PMSF, 20
μg/ml aprotinin) and phosphatase inhibitor (2 mM Na3VO4). Protein extracts were
immunoprecipitated with rabbit polyclonal antibodies specific for the IGF-IR β-chain (SC713;
Santa Cruz Biotechnology, Santa Cruz, CA), IRS-1 [JD-288 (1), SC-559, SC-560; Santa Cruz],
IRS-2 [JD-250 (1), SC-8298; Santa Cruz], or Shc (SC-1695; Santa Cruz). Immunoprecipitates
were electrophoresed on 8.5% (IGF-IR, IRS-1, and IRS-2) or 12% (Shc) SDS polyacrylamide
gels and were transferred to PVDF membranes (Immobilon-P, Millipore, Bedford, MA).
Immunoblots were probed with IGF-IR, IRS-1, IRS-2, or Shc antibodies. Immunoreactive
proteins were identified by using the ECL detection system (PerkinElmer Life Sciences,
Boston, MA) and published methods (1,19). Abundance of immunoprecipitated proteins was
quantified by using ImageQuant (version 1.2; Molecular Dynamics, Sunnyvale, CA) software
analysis of autoradiographs.
In vitro analyses
IEC-6, a nontransformed intestinal epithelial cell line from rat small intestine, was obtained
from the American Type Culture Collection, cultured as previously described, and used at
passages 12–20 (19). Primary cultures of intestinal myofibroblasts were prepared from
IRS-1+/+ and IRS-1−/− mice as previously described (24). Myofibroblast phenotype was
confirmed by immunoblotting for α-smooth muscle actin and vimentin (18). Subconfluent
myofibroblasts were studied at passages 4–6. IEC-6 cells or intestinal myofibroblasts were
serum deprived for 24 h before treatment with IGF-I to analyze early signaling intermediates.
Analyses of IRS-1, IRS-2, and Shc were performed by using immunoprecipitation and
immunoblotting as described in Expression of IGF-I signaling molecules in the intestine.
Tyrosine-phosphorylated proteins were detected by using anti-phosphotyrosine antibodies
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(4G10, Upstate Biotechnology, Lake Placid, NY and PY20, Zymed Laboratories, South San
Francisco, CA).
Data analysis and statistics
Values are expressed as means ± SE. Absolute values for bowel mass in IRS-1−/− and
IRS-1+/+ littermates were compared by the Mann-Whitney U-test as independent groups. In
addition, values in each IRS-1−/− mouse were expressed as a ratio of the corresponding value
in a sex-matched littermate pair. Mean ratios for different measurements of intestinal growth
were compared for a significant difference from 1 by using Wilcoxon signed-rank analyses or
from each other by using the Mann-Whitney U-test. Mean measurements of bowel growth
(bowel weight, length, DNA, protein, mitoses, and apoptosis) in IGF-I transgenics with
different IRS-1 genotype were analyzed by two-factor ANOVA for significant main effects of
IRS-1 gene deletion or the IGF-I transgene and for an interaction between IRS-1 gene deletion
and IGF-I transgene. A significant interaction between IRS-1 gene deletion and IGF-I
transgene provides statistical evidence that IRS-1 deficiency influences the magnitude of IGF-
I-induced growth. Tukey’s test was used for post hoc, pair-wise comparisons between IGF-I
transgenic and WT mice of each IRS-1 genotype or comparison between IRS-1−/−/WT and
IRS-1+/+/WT mice. A P value of <0.05 was considered statistically significant.
The animal studies were approved by the Institutional Animal Care and Use Committee of the
University of North Carolina at Chapel Hill. Study protocols were in compliance with the Guide
for the Care and Use of Laboratory Animals published by the National Institutes of Health.
RESULTS
Effects of absolute IRS-1 deficiency on growth of jejunum and colon
Compared with IRS-1+/+ littermates, IRS-1−/− mice exhibited markedly reduced body weight
(58 ± 5% of WT littermates; P < 0.01) and decreased weight and length of entire small intestine
and colon (Table 1). More detailed analyses demonstrated reduced DNA content in the jejunal
mucosa (63 ± 7% of IRS-1+/+ littermates), whereas mucosal wet weight, protein content, and
sucrase activity were unaffected by IRS-1 deficiency (Table 2A). Crypt mitoses were reduced
in the jejunal mucosa of IRS-1−/− mice (1.9 ± 0.15) relative to IRS-1+/+ mice (vs. 3.0 ± 0.17;
P < 0.05). In jejunal muscularis, wet weight, protein content, and DNA content were all
significantly decreased in IRS-1−/− mice compared with IRS-1+/+ littermates (Table 2A).
In the colon of IRS-1−/− mice, mucosal weight was significantly reduced to 75 ± 7% of the
value in IRS-1+/+ mice and mucosal weight to 67 ± 5% (P < 0.05). There were parallel and
proportionate decreases in DNA and protein (Table 2B). As in the jejunum, there were
significantly lower rates of mitoses per crypt in IRS-1−/− mice (3.3 ± 0.36) compared with
IRS-1+/+ mice (4.6 ± 0.32; P < 0.05). Myocyte numbers per unit area (1,000 μm2) were not
significantly different in colon of IRS-1−/− mice (3 ± 0.09) vs. IRS-1+/+ littermates (3 ± 0.08;
P = 0.257), indicating that the average size of enteric smooth muscle cells did not change.
Consistent with the biochemical data, qualitative evaluation of histological sections of jejunum
from IRS-1−/− and IRS-1+/+ mice revealed no major effect of IRS-1 deficiency on mucosal
thickness, whereas the muscularis thickness was reduced (Fig. 1, A and B). In the colon,
thickness of both mucosa and muscularis layers was decreased in IRS-1-null mice (Fig. 1, C
and D).
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Expression of IGF-IR and associated signaling molecules in the small intestine and colon of
IRS-1−/− and IRS-1+/+ mice
IGF-IR, IRS-1, IRS-2, and Shc were evaluated in the mucosa and muscularis of IRS-1+/+ and
IRS-1−/− jejunum and colon by immunoprecipitation followed by immunoblotting. All of the
signaling molecules were low-abundance proteins requiring immunoprecipitation of at least 8
mg of total protein extract to detect IRS-1 or IRS-2, 3 mg to detect IGF-IR, and 0.2 mg to detect
Shc. Figure 2 shows representative Western immunoblots. In IRS-1+/+ and IRS-1−/− mice, IGF-
IR and IRS-2 were much more readily detected in colonic mucosa and muscularis (P < 0.05;
n ≥ 4 for both mediators) than in small intestine (Fig. 2). Figure 2 also shows that in WT mice,
IRS-1 is detected with higher levels in colon than small intestine (P < 0.05; n ≥ 4), whereas
little or no IRS-1 is detectable in small intestine or colon of IRS-1−/− mice.
To assess whether IRS-1 deficiency caused compensatory changes in the levels of IGF-IR or
IRS-2 and Shc, the major alternative signaling molecules to IRS-1, levels of expression of each
intermediate in mucosa or muscularis of IRS-1+/+ mice were expressed as a ratio of the levels
in corresponding samples from IRS-1+/+ littermates analyzed on the same blots. Mean values
across replicate samples are shown in Table 3. IRS-1 deficiency did not significantly affect the
levels of IGF-IR or IRS-2 in small intestine or colon (Table 3). In colon, there were small but
significant increases in Shc expression in both mucosa and muscularis of IRS-1−/− vs.
IRS-1+/+ mice, and there was a similar but nonsignificant trend toward increased Shc in small
intestine of IRS-1−/− mice (Table 3).
The higher levels of expression of IGF-IR and major IGF-IR signaling substrates in colon than
those found in small intestine and the effects of IRS-1 deficiency on growth of both mucosal
and muscularis layers of the colon prompted us to focus subsequent analyses on the colon.
Absolute IRS-1 deficiency impairs MT-hIGF-I-dependent growth of colonic mucosa but not
muscularis
Mass of colonic mucosa and muscularis was assayed in MT-hIGF-I transgenic and WT mice
with two or zero functional IRS-1 alleles to specifically test whether IRS-1 is required for
trophic actions of IGF-I on the intestine in vivo. Overexpression of the MT-hIGF-I transgene
increased mucosal wet weight (P < 0.001), protein content (P < 0.001), and DNA content (P
< 0.001) in the colon of both IRS-1+/+ and IRS-1−/− mice, indicating that IRS-1 is not absolutely
required for IGF-I-stimulated mucosal growth (Fig. 3). However, the magnitude of MT-hIGF-
I-dependent mucosal growth was significantly lower in IRS-1−/− mice than in IRS-1+/+ mice
(Fig. 3A), suggesting that the absence of IRS-1 impaired the growth-promoting effects of IGF-
I on colonic mucosa. Two-way ANOVA confirmed significant interactions between the IGF-
I transgene and IRS-1 deficiency on mucosal growth (interaction: P < 0.001 for wet weight,
protein content, and DNA content). Thus these results indicate that, in vivo, MT-hIGF-I-
induced overgrowth of colonic mucosa is partially dependent on IRS-1.
As illustrated in Fig. 3B, wet weight, protein content, and DNA content in the colonic
muscularis layer of IRS-1+/+/MT-hIGF-I mice were significantly increased compared with
values in IRS-1+/+/WT mice. Absolute IRS-1 deficiency did not abolish the IGF-I-induced
muscularis growth (Fig. 3B). Indeed, lack of IRS-1 did not even attenuate MT-hIGF-I
transgene-induced overgrowth of the muscularis (Fig. 3B; interaction: wet weight, P = 0.06;
protein content, P = 0.362; DNA content, P = 0.691). These results were not due to lack of
effects of IRS-1 deficiency on muscularis because two-way ANOVA revealed significant, main
effects of IRS-1 deficiency to reduce all measures of muscularis mass (P < 0.001). Therefore,
although IRS-1 deficiency reduces the mass of colonic muscularis, the overgrowth of the
muscularis induced by MT-hIGF-I transgene overexpression in vivo does not require IRS-1
and is not attenuated by IRS-1 deficiency. Histology in Fig. 4 shows representative examples
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of colon from IRS-1+/+/WT, IRS-1+/+/MT-hIGF-I, IRS-1−/−/WT, and IRS-1−/−/MT-hIGF-I,
which are consistent with biochemical findings.
Absolute IRS-1 deficiency does not impair SMP8-IGF-I-dependent muscularis growth
To confirm that muscularis overgrowth induced by IGF-I overexpression did not depend on
IRS-1, we analyzed muscularis growth in WT or SMP8-IGF-I transgenic mice with two or zero
copies of IRS-1. Consistent with our previous observations (28), SMP8-IGF-I transgenic mice
with two functional IRS-1 alleles showed major increases in wet weight, protein content, and
DNA content of colonic muscularis compared with WT (IRS-1+/+ mice) (Fig. 5). IRS-1
deficiency had no significant impact on the magnitude of SMP8-IGF-I transgene-induced
growth of colonic muscularis (Fig. 5).
IRS-1 deficiency attenuates the antiapoptotic, but not mitogenic, actions of IGF-I in colonic
mucosa
As found previously for small intestine (27), MT-hIGF transgene expression significantly
increased crypt mitoses in colon of mice with two intact copies of the IRS-1 gene (Fig. 6).
Crypt mitoses were also significantly increased in colon of IRS-1-deficient MT-hIGF-I
transgenics. The increase was modestly attenuated compared with IRS-1+/+/MT-hIGF-I mice,
but two-way ANOVA revealed no significant interaction between transgene and IRS-1 gene
deletion (P = 0.369). We therefore tested whether IRS-1 deficiency impaired the antiapoptotic
effects of IGF-I on colonic mucosa. As found previously in small intestine, MT-hIGF-I
transgene decreased apoptosis in colon of IRS-1+/+ mice (P < 0.0001), but this effect was
abolished in mice homozygous for IRS-1 gene disruption (Fig. 6). Two-way ANOVA
confirmed a significant interaction (P < 0.01) between IGF-I transgene and IRS-1 deficiency
on spontaneous apoptosis in colon.
Analyses of IGF-IR signaling in cultured intestinal epithelial cells and mesenchymal cells
We tested early signaling intermediates activated by IGF-I in cultured epithelial and
mesenchymal cells derived from the intestine to investigate the possible mechanisms for
differential dependence on IRS-1 in the mucosa and muscularis. Nontransformed IEC-6 cells
were used as a model for the intestinal epithelium because quantitative studies of IRS-1 or
IRS-2 in mucosal extracts or isolated crypts proved impractical due to their low abundance and
the large amounts of protein required for analyses. In IEC-6 cells, immunoblots revealed high-
level expression of IRS-1, whereas IRS-2 was barely detectable (Fig. 7). IGF-I induced robust
tyrosine phosphorylation of IRS-1, with maximum phosphorylation of IRS-1 at 3 min after
stimulation, whereas no tyrosine phosphorylation of IRS-2 was detected at the same (Fig. 7)
or later times (unpublished data). Shc was activated by IGF-I in IEC-6 cells (Fig. 7).
Dose-dependent tyrosine phosphorylation of IGF-IR, IRS-1, IRS-2, and Shc was also examined
in primary cultures of intestinal myofibroblasts from IRS-1+/+ and IRS-1−/− mice at 3 min after
IGF-I stimulation, when IGF-I induces maximal IRS phosphorylation in these cells
(unpublished results). Representative immunoblots are shown in Fig. 8, and quantitative data
are presented in Fig. 9. IRS-1+/+ myofibroblasts show robust tyrosine phosphorylation of IGF-
IR, IRS-1, IRS-2, and Shc following IGF-I stimulation. In IRS-1−/− myofibroblasts, there was
no expression or tyrosine phosphorylation of IRS-1, but IGF-IR, IRS-2, and Shc were all
activated by IGF-I (Fig. 8). IRS-1+/+ and IRS-1−/− myofibroblasts did not differ in the IGF-I-
induced activation of IGF-IR (P > 0.05 at all doses; Fig. 9) or Shc (P > 0.05 at all doses; Fig.
9). Activation of IRS-2 by IGF-I was dramatically increased in IRS-1−/− myofibroblasts
compared with IRS-1+/+ cells (P < 0.001 at the 50- and 200-ng doses of IGF-I; maximum IRS-2
activation in IRS-1+/+ cells was 4.9 ± 1.0-fold at the 50-ng dose of IGF-I, whereas maximum
activation of IRS-2 in IRS-1−/− myofibroblasts was 15.4 ± 3.9-fold; Fig. 9). This provides
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evidence for compensatory increases in the ability of IGF-I to activate the alternate signaling
molecule IRS-2, but not Shc, in IRS-1-deficient intestinal mesenchymal cells.
DISCUSSION
Our results demonstrate that absolute IRS-1 deficiency significantly impairs growth of both
mucosa and muscularis layers in jejunum and colon. This finding extends the evidence that
IRS-1 plays a key role in mediating normal intestinal growth in vivo (1,16). Absolute IRS-1
deficiency led to reduced crypt-cell mitoses in both jejunum and colon. This impaired crypt-
cell proliferation is consistent with in vitro findings that chicken hepatoma cells and embryonic
fibroblasts require IRS-1 for normal cell proliferation (4,20). Interestingly, mass of small
intestinal and colonic mucosa showed a differential dependence on IRS-1. Only DNA content,
but not protein content, was significantly reduced in jejunal mucosa of IRS-1−/− mice, whereas
colonic mucosa showed dramatic decreases in both DNA and protein. These results indicate
that jejunal mucosa may compensate more effectively than colonic mucosa for the impaired
cell proliferation resulting from absolute IRS-1 deficiency by increasing the amount of protein
synthesized per cell and/or cell size so that there is no discernible effect on overall mucosal
mass, despite reduced cell proliferation. It seems plausible that either humoral or local factors,
which act independently of IRS-1, or direct or indirect effects of nutrients may serve to maintain
protein levels in jejunal mucosa during IRS-1 deficiency. Consistent with this concept, growth
of jejunal mucosa is much more responsive to nutrient levels than colon (29), and recent reports
demonstrate that high calorie intake or enteral nutrient combined with trophic hormones act to
increase mucosal protein more than DNA content (12,14). In addition, our results indicate that
in the jejunal mucosa of both IRS-1+/+ and IRS-1−/− mice, Shc is expressed at higher levels
than IRS proteins, suggesting that it may be a predominant mediator of mucosal growth in this
segment. Normal levels of sucrase in the intestine of IRS-1-null mice suggest a preferential
requirement for IRS-1 as a mediator of crypt proliferation vs. enterocyte differentiation in vivo.
This is consistent with data from 32D cells, in which IRS-1 is required for cell growth but not
cell differentiation (23,26).
Our analyses of muscularis indicate that IRS-1 is required for normal cell number in muscularis
layers of the intestine in vivo. This is consistent with findings in skeletal muscle cells that
normal or IGF-I-dependent growth of gastrocnemius muscle requires IRS-1 (16). Decreased
thickness of intestinal muscularis layers but no significant change in cell size in IRS-1-null
mice suggests that reduced cell number is responsible for the effects of IRS-1 deficiency on
muscularis growth. This likely reflects decreased enteric smooth muscle cell proliferation
because a lack of IRS-1 has been found to impair proliferation of other mesenchymal cell types
in vitro (4).
In intestine of IRS-1-null mice in vivo, there was no evidence for increased levels of IGF-IR
or the major alternative signaling molecule, IRS-2, in the mucosa or muscularis. There appear
to be tissue-specific differences in compensatory responses to IRS-1 deficiency, because in
brain of IRS-1-deficient mice there is upregulation of IRS-2 levels (30). Intriguingly, specific
increases in IRS-2 in the brain are also associated with minimal effects of IRS-1 deficiency on
normal or IGF-I-stimulated brain growth (30). Shc expression was modestly increased in both
colonic mucosa and muscularis of IRS-1-null mice, but this was not sufficient to prevent the
reduced mass and growth of these layers that was observed in IRS-1-deficient mice.
We used cross-bred mice expressing IGF-I transgenes on a background of two or zero intact
IRS-1 genes to specifically assess whether IRS-1 deficiency impairs the actions of IGF-1 on
mucosa or muscularis in vivo. MT-hIGF-I transgene over-expression potently stimulated
growth of both mucosal and muscularis layers of colon, with >200% increases in protein and
DNA content in IRS-1+/+/MT-hIGF-I mice vs. IRS-1+/+/WT. These effects of the MT-hIGF-
Simmons et al. Page 7













I transgene on the colonic mucosa are greater in magnitude than previously observed for small
intestine (15), consistent with our current observations of higher-level expression of IGF-IR
and signaling molecules in the colonic vs. jejunal mucosa. The greater IGF-I responsiveness
of normal colon vs. small intestinal mucosa is relevant to the increasing evidence that elevated
IGF-I is a risk factor for colorectal adenoma or cancer (7).
Our observations that IRS-1 deficiency attenuates the magnitude of IGF-I-induced overgrowth
of mucosa, but not muscularis, provide novel evidence for cell type-specific dependence on
IRS-1 for IGF-I-induced colon growth in vivo.
In the colon, IGF-I-induced mucosal growth was only partially dependent on IRS-1, with a
50–65% attenuation of the IGF-I-induced increases in DNA and protein in IRS-1-deficient
mice. Surprisingly, this was associated with only slightly attenuated mitogenic effects of IGF-
I in colonic crypts of IRS-1-null mice, whereas antiapoptotic effects of IGF-I were completely
abolished by IRS-1 deficiency. Although IGF-IR/IRS-1-activated pathways have been linked
to antiapoptotic actions of IGF-I in cancer cell lines derived from the intestine, there is little
or no information about in vivo signal-transduction pathways required for the antiapoptotic
actions of IGF-I. Our observations demonstrate that one key IGF-I signaling molecule, IRS-1,
is required for protective actions of IGF-I against crypt cell apoptosis in vivo.
The fact that IRS-1 deficiency did not impair IGF-I-dependent growth of colon muscularis
demonstrates that enteric smooth muscle does not require IRS-1 for IGF-I-dependent growth.
It is well known that growth of intestinal smooth muscle cells in vitro can be regulated by IGF-
I (10,31) and that IGF-I stimulation recruits IRS-1 to IGF-IR (9); however, little information
is available about the primary signaling molecules that are required for IGF-I-induced enteric
smooth muscle cell growth in vivo. Our prior in vivo study indicated that IRS-1 is required for
IGF-I-dependent growth in skeletal muscle cells (16), and studies in cultured embryonic
fibroblasts indicate that normal growth of some mesenchymal cell types requires IRS-1 (4).
Thus enteric smooth muscle cells differ from other mesenchymal cells in the lack of dependence
on IRS-1. IRS-2 and Shc, which we found to be expressed in intestinal muscularis, could serve
as alternate mediators of IGF-I action rather than IRS-1. The significant 80% increase in Shc
levels observed in colon muscularis of IRS-1-null mice suggests that Shc may serve as an
alternate signaling molecule for IRS-1 action in colon muscularis. We attempted to test whether
tyrosine phosphorylation of Shc or IRS-2 was upregulated in colon muscularis of IRS-1−/−/
MT-hIGF-1 compared with IRS-1+/+/MT-hIGF-I mice, but this proved problematic because
of low-level IRS-2 expression and inability to consistently detect tyrosine-phosphorylated
proteins in tissue extracts. However, studies in primary mesenchymal-cell cultures demonstrate
that IGF-I-dependent IRS-2 activation, but not Shc activation, was dramatically upregulated
in IRS-1−/− intestinal mesenchymal cells on IGF-I stimulation. Intestinal mesenchymal cells
differ from IRS-1−/− embryonic fibroblasts, which do not show upregulated activation of
alternative signaling molecules (4), further pointing to cell- and tissue-specific differences in
IGF-I signaling pathways.
The lack of dependence on IRS-1 for IGF-I-induced muscularis growth in vivo appears
paradoxical given the reduced mass of enteric smooth muscle layers in IRS-1−/− mice relative
to IRS-1+/+ mice. This suggests that normal growth of intestinal muscularis is regulated by
other IRS-1-linked hormones than IGF-I, which could include growth hormone and angiotensin
II, which both have trophic effects on smooth muscle and both activate IRS-1 (6,17).
Normal MT-hIGF-1-mediated muscularis overgrowth in IRS-1−/− mice could reflect some
compensatory responses to long-term elevations of circulating IGF-I that occur in these
transgenics. We therefore used a second model, SMP8-IGF-I/WT and SMP8-IGF-I/IRS-1−/−
mice, to directly assess the requirement of the intestine for IRS-1 in mediating autocrine/
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paracrine actions of IGF-I expressed specifically in the intestinal muscularis layers. Our results
in these mice provide independent confirmation that IRS-1 is not required for IGF-I-mediated
growth of the muscularis. SMP8-IGF-I transgenics show no increase in plasma levels of IGF-
I (25,28) and, therefore, results in these mice are not confounded by secondary effects that
could occur due to long-term effects of elevated circulating IGF-I.
We can only speculate on the biological reason why the colonic epithelium should have greater
dependence on IRS-1 for growth-promoting and antiapoptotic actions of IGF-I compared with
muscularis. Low apoptosis within colonic crypts is linked to increased risk the development
of precancerous adenomatous lesions within the colonic epithelium (8), and much evidence
suggests a role of IGF-I in colon cancer risk (7). The dependence of the epithelium but not
muscularis on IRS-1 may therefore serve as a protective mechanism against protumorigenic
effects of IRS-1.
In conclusion, our findings provide new in vivo evidence for cell type-specific requirements
for IRS-1 as a mediator of normal or IGF-I-induced intestinal growth that could not have been
predicted from in vitro findings or observations in other tissues. Specifically, 1) normal crypt
cell mitoses in colonic and jejunal mucosa require IRS-1; 2) in jejunal mucosa, normal DNA
but not protein or sucrase activity in the mucosa requires IRS-1, whereas in colon, DNA and
protein content are both affected by IRS-1 deficiency; 3) using a cross-breeding approach to
generate mice that overexpress IGF-I on a background of normal or zero levels of IRS-1, we
demonstrated that mucosa, but not muscularis, shows partial dependence on IRS-1 for IGF-I-
induced growth in vivo; 4) the mucosal growth deficit in IRS-1−/−/MT-hIGF-I mice involves
impaired ability of IGF-I to reduce apoptosis rather than impaired mitogenic actions; 5) in vitro
findings indicate that IRS-1 is used in preference to IRS-2 to mediate IGF-I action in intestinal
epithelial cells, whereas intestinal mesenchymal cells use both IRS-1 and IRS-2 to mediate
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Effects of absolute insulin receptor substrate (IRS)-1 deficiency on mass of mucosa and
muscularis layers in small intestine and colon. Photomicrographs of representative
hematoxylin and eosin-stained sections of jejunum and colon from IRS-1+/+ (A and C) and
IRS-1−/− (B and D) mice are shown. Bar = 100 μm. Note attenuated thickness of muscularis
but not of mucosal layer in IRS-1−/− jejunum and attenuated thickness of both layers in colon.
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Expression levels of total insulin-like growth factor-I receptor 1 (IGF-IR), IRS-1, IRS-2, and
Src homology 2 domain and collagen protein (Shc) in small intestine and colon of IRS-1+/+
(WT) and IRS-1−/− (KO) mice. Protein extracts from mucosa (mc) and muscularis (ms) of
small intestine and colon were immunoprecipitated (IP) with antibodies specific for IGF-IR,
IRS-1, IRS-2, and Shc, as described in EXPERIMENTAL PROCEDURES.
Immunoprecipitates were resolved by SDS-PAGE and were immunoblotted with indicated
antibodies. Note faint, more slowly migrating band in IRS-1−/− extracts has been observed in
analyses of other tissues from IRS-1−/− mice and probably reflects cross-reactivity of IRS-1
proteins with IRS-2 (1). Figure is representative of 4 or more independent experiments.
Numbered arrows at left indicate locations of molecular-weight markers electrophoresed on
same gel.
Simmons et al. Page 13














Effects of absolute IRS-1 deficiency on mass of colonic mucosa and muscularis in wild-type
(WT) mice and mice that overexpress a human IGF-I transgene driven by a mouse
metallothionein-1 promoter (MT-hIGF-I trans-genic mice). Histograms show means ± SE for
wet weight, DNA, and protein content per centimeter of colonic mucosa (A) or colonic
muscularis (B). Muscularis mass in colon in IRS-1+/+/WT (closed bar), IRS-1+/+/MT-hIGF-I
(gray bar), IRS-1−/−/WT (hatched bar), or IRS-1−/−/MT-hIGF-I mice (cross-hatched bar) is
shown. Numbers above histograms are mean values in MT-hIGF-I transgenics expressed as a
percentage of values in WT mice of same IRS-1 genotype to indicate magnitude of MT-hIGF-
I-dependent bowel growth. Results of 2-way ANOVA analyses on absolute values are shown,
where *P < 0.001 and not significant (NS) = P > 0.05. ANOVA analyses are described in more
detail in supplemental material, available on American Journal of Physiology-Gastrointestinal
and Liver Physiology website.
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Effects of IGF-I transgenes on mass of mucosa and muscularis in colon of WT and IRS-1-
deficient mice. Photomicrographs of hematoxylin and eosin-stained sections of colon from
IRS-1+/+/WT (A), IRS-1+/+/MT-hIGF-I (B), IRS-1−/−/WT (C), and IRS-1−/−/MT-hIGF-I (D)
mice are shown.
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Effects of absolute IRS-1 deficiency on muscularis overgrowth induced by SMP8-IGF-I
transgene. Muscularis mass in colon in IRS-1+/+/WT (closed bar), IRS-1+/+/SMP8-IGF-I (gray
bar), IRS-1−/−/WT (hatched bar), or IRS-1−/−/SMP8-IGF-I (cross-hatched bar) mice.
Histograms show absolute values for wet weight, DNA, and protein content per centimeter
expressed as means ± SE; n = 12. Numbers above histograms show mean values in SMP8-
IGF-I mice expressed as a percentage of values in WT mice of same IRS-1 genotype. Results
of 2-way ANOVA are shown, where *P < 0.001 and NS = P > 0.05. Two-way ANOVA
revealed significant main effects of SMP8-IGF-I transgene and significant main effects of
absolute IRS-1 deficiency but no significant interaction. ANOVA analyses are described in
more detail in supplemental material, available on American Journal of Physiology-
Gastrointestinal and Liver Physiology website.
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IRS-1 is required for antiapoptotic but not proliferative effects of transgene-derived IGF-I.
Histograms show levels of spontaneous mitoses (A) and apoptosis (B) in colonic mucosa of
IRS-1+/+/WT (closed bar), IRS-1+/+/MT-hIGF-I (gray bar), IRS-1−/−/WT (hatched bar), and
IRS-1−/−/MT-hIGF-I mice (cross-hatched bar). Numbers above histograms show magnitude
of significant changes observed in MT-hIGF-I transgenics relative to WT mice of same IRS-1
genotype. Note that IRS-1+/+/MT-hIGF-I mice showed reduced apoptosis compared with
IRS-1+/+/WT but that apoptosis in IRS-1−/−/MT-hIGF-I mice did not differ significantly from
IRS-1−/−/WT mice. Results of 2-way ANOVA are shown below histograms, where *P < 0.05
for main effect of MT-hIGF-1 transgene, IRS-1 gene deletion, or interaction between transgene
and IRS-1 deletion. NS = P > 0.05; n = 100 crypts assayed in at least 4 mice of each genotype.
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Expression and phosphorylation of IRS-1 and IRS-2 in IEC-6 rat intestinal epithelial cells.
IEC-6 were serum-starved for 24 h and were treated with IGF-I (100 ng/ml) for indicated times.
Cells were lysed and then immunoprecipitated with IRS-1, IRS-2, or Shc antibodies.
Immunoprecipitates were electrophoresed and then immunoblotted (IB) with indicated
antibodies. Immunoblots are representative of at least 4 independent experiments.
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Expression and phosphorylation of IGF-IR signaling molecules in cultured intestinal
mesenchymal cells. Intestinal myofibroblasts were derived from IRS-1+/+ and IRS-1−/− mice
as described in EXPERIMENTAL PROCEDURES Cells were serum starved for 24 h and were
treated with IGF-I at different doses. Cell extracts were immunoprecipitated with antibodies
against IRS-1, IRS-2, IGF-IR, or Shc and were immunoblotted with indicated antibodies.
Immunoblots are representative of at least 4 separate experiments.
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Magnitude of IGF-I-induced tyrosine phosphorylation of IGF-IR, IRS-2, and Shc in
IRS-1+/+ (●) and IRS-1−/− (○) myofibroblasts. Intestinal myofibroblasts from IRS-1+/+ and
IRS-1−/− mice were serum starved and were treated with IGF-I at different doses. Cell extracts
were immunoprecipitated with antibodies against IGF-IR, IRS-2, or Shc and were
immunoblotted with anti-phosphotyrosine antibodies or antibodies to total protein. Data points
represent fold increases in tyrosine-phosphorylated protein vs. zero dose of IGF-I. Each data
point represents a mean ± SE; n ≥ 4 independent experiments. aP < 0.05 in IRS-1−/− cells vs.
IRS-1+/+ cells.
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Table 1
Effects of absolute IRS-1 deficiency on weight, length, and weight per unit length
of the small intestine and colon
Weight, g Length, cm Weight per Unit Length, mg/cm
Small Intestine
 IRS-1+/+ 1.29±0.07 43.63±0.71 30.45±1.45
 IRS-1−/− 0.92±0.03* 39.04±1.23* 24.04±1.72*
Colon
 IRS-1+/+ 0.35±0.3 10.3±0.22 33.8±2.7
 IRS-1−/− 0.22±0.01* 8.9±0.24# 24.4±4*
Data are means ± SE of absolute values from at least 6 insulin receptor substrate (IRS)-1−/− and IRS-1+/+ littermate pairs.
*
P < 0.05 between IRS-1+/+ and IRS-1−/− mice;
#
P = 0.066.
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Table 3
Mean levels of IGF-IR, IRS-2, and Shc in small intestine or colon mucosa and










Data are means ± SE; n ≥ 4 independent analyses on extracts prepared from different littermate pairs. Signal intensities for each mediator in IRS-1−/−
extracts were expressed as ratio of values in corresponding mucosal or muscularis extract of IRS-1+/+ littermate evaluated in same immunoprecipitation/
immunoblot experiment. IGF-IR, insulin-like growth factor-I receptor; Shc, Src homology 2 domain and collagen protein. Wilcoxon signed rank tested
whether ratios differed from 1;
*
P < 0.05.
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